bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2022-56-3-113-118bekhterev-725Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR THE PRACTITIONERЭффективность вортиоксетина у пациентов с депрессией в реальной клинической практикеThe effectiveness of vortioxetine in patients with depression in real clinical practicehttps://orcid.org/0000-0003-4096-6208ПетроваН. Н.PetrovaN. N.

Петрова Наталия Николаевна – д.м.н., профессор, заведующая кафедрой психиатрии и наркологии

Санкт-Петербург

Nataliia N. Petrova

St. Petersburg

petrova_nn@mail.ruСанкт-Петербургский государственный университетРоссияSaint Petersburg State UniversityRussian Federation202215102022563113118Copyright © Петрова Н.Н., 20222022Петрова Н.Н.Petrova N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/725

Статья-мнение посвящена анализу масштабного 24-недельного многонационального обсервационного проспективного когортного исследования «Эффективность вортиоксетина при депрессии в реальной клинической практике» (RELIEVE). Исследование продемонстрировало достижение функционального восстановления пациентов с депрессивным расстройством при применении вортиоксетина, хорошую эффективность и переносимость препарата для лечения депрессии в большой и гетерогенной популяции пациентов, репрезентативной для повседневной психиатрической практики. Достигнуто значимое улучшение депрессивных и когнитивных симптомов, производительности и качества жизни пациентов, при этом наибольший эффект наблюдался при использовании вортиоксетина в качестве первой линии терапии. Результаты исследования подтвердили данные многочисленных РКИ, посвященных применению вортиоксетина в лечении депрессивного расстройства, и их можно использовать при выборе тактики антидепрессивной терапии в условиях рутинной психиатрической практики.

The opinion article is devoted to the analysis of a large-scale 24-week multinational observational prospective cohort study «The effectiveness of vortioxetine in depression in real clinical practice» (BELIEVE). The study demonstrated the achievement of functional recovery of patients with depressive disorder when using vortioxetine, good efficacy and tolerability of the drug for the treatment of depression in a large and heterogeneous patient population representative of everyday psychiatric practice. A significant improvement in depressive and cognitive symptoms, productivity and quality of life of patients was achieved, while the greatest effect was observed when using vortioxetine as the first line of therapy. The results of the study confirmed the data of numerous RCTs devoted to the use of vortioxetine in the treatment of depressive disorder, and they can be used when choosing tactics of antidepressant therapy in conditions of routine psychiatric.

вортиоксетинклиническая эффективностьпереносимостьреальная клиническая практикаvortioxetineclinical efficacytolerabilityreal clinical practiceReferencesКлинические рекомендации «Депрессивный эпизод, Рекуррентное депрессивное расстройство» [diseases.medelement.com]. diseases.medelement; 2021 [процитировано 3 сентября 2022]. Доступно: https://yandex.ru/search/?clid=2285101&text=september&lr=2Клинические рекомендации «Депрессивный эпизод, Рекуррентное депрессивное расстройство» [diseases.medelement.com]. diseases.medelement; 2021 [процитировано 3 сентября 2022]. Доступно: https://yandex.ru/search/?clid=2285101&text=september&lr=2Колбин А.С., Белоусов Д.Ю., Зырянов С.К. и др, Исследования реальной клинической практики. Под ред. А.С. Колбина. М.: Издательство ОКИ: Буки Веди, 2020.Kolbin A.S., Belousov D.Yu., Zyryanov S.K. et al. Issledovaniya real’noj klinicheskoj praktiki. Pod red. A.S. Kolbina. M.: Izdatel’stvo OKI: Buki Vedi, 2020. (In Russ.).Марцевич С.Ю., Кутишенко Н.П. Рандомизированные клинические исследования и наблюдательные исследования: соотношение в иерархии доказательств эффективности лекарств. Рациональная Фармакотерапия в Кардиологии. 2016;12(5):567-573.Martsevich SYu, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs. Racional’naya Farmakoterapiya v Kardiologii. 2016;12(5):567-573. (In Russ). http//doi.org/10.20996/1819-6446-2016-12-5-567-573Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. Еще раз об иерархии доказательств в медицине, или можно ли с помощью наблюдательных исследований решить вопрос о выборе наиболее эффективного и безопасного препарата. Рациональная Фармакотерапия в Кардиологии. 2017;13(2):270-274.Martsevich SYu, Lukina YuV, Kutishenko NP. Once again about the Hierarchy of Evidences in Medicine or whether it is Possible to Choose the Most Effective and Safe Drug with the Help of Observational Studies. Racional’naya Farmakoterapiya v Kardiologii. 2017;13(2):270-274. (In Russ.). http//doi.org/10.20996/1819-6446-2017-13-2-270-274Петрова Н.Н., Савицкая К.С. Диагностика и терапия коморбидных тревожных и депрессивных расстройств в клинической практике. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2021;1:92-102.Petrova NN, Savitskaya KS. Diagnosis and therapy of comorbid anxiety and depressive disorders in clinical practice. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. 2021;1:92-102. (In Russ.). http//doi.org/10.31363/2313-7053-2021-1-3-1Петрова Н.Н., Палкин Ю.Р., Фаддеев Д.В., Зиновьева А.Г. Коморбидность депрессивных и тревожных расстройств в клинической практике. Журнал неврологии и психиатрии им. C.C. Корсакова. 2021;121(4):31-37.Petrova NN, Palkin YuR, Faddeev DV, Zinovieva AG. Comorbidity of depressive and anxiety disorders in clinical practice. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2021;121(4): 31-37. (In Russ.).Awad AG. ‘The patient’: at the center of patientreported outcomes. Expert Rev Pharmacoecon Outcomes Res. 2015;15:729–731. http//doi.org/10.1586/14737167.2015.1077118Awad AG. ‘The patient’: at the center of patientreported outcomes. Expert Rev Pharmacoecon Outcomes Res. 2015;15:729–731. http//doi.org/10.1586/14737167.2015.1077118Baldwin DS, Chrones L, Florea I et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016; 30:242–52. http//doi.org/10.1177/0269881116628440Baldwin DS, Chrones L, Florea I et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016; 30:242–52. http//doi.org/10.1177/0269881116628440Chen G, Højer AM, Areberg J et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686.Chen G, Højer AM, Areberg J et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686.Chen G, Lee R, Højer AM et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–736.Chen G, Lee R, Højer AM et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–736.Chen G, Nomikos GG, Affinito J et al. Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet. 2016;55(9):1115-1127.Chen G, Nomikos GG, Affinito J et al. Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet. 2016;55(9):1115-1127.Chin CN, Zain A, Hemrungrojn S et al. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin. 2018; 34:1975–84. http//doi.org/10.1080/03007995.2018.1477746Chin CN, Zain A, Hemrungrojn S et al. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin. 2018; 34:1975–84. http//doi.org/10.1080/03007995.2018.1477746Chokka P, Bougie J, Proulx J et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.CNS Spectr. 2019;24:616–627. http//doi.org/10.1017/S1092852919000786Chokka P, Bougie J, Proulx J et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.CNS Spectr. 2019;24:616–627. http//doi.org/10.1017/S1092852919000786Chokka P, Ge H, Bougie J et al. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the At-WoRC study. Ther Adv Psychopharmacol. 2021; 11:20451253211013148. http//doi.org/10.1177/20451253211013148Chokka P, Ge H, Bougie J et al. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the At-WoRC study. Ther Adv Psychopharmacol. 2021; 11:20451253211013148. http//doi.org/10.1177/20451253211013148Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study. J Occup Environ Med. 2020;62:e94–101. http//doi.org/10.1097/JOM.0000000000001805Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study. J Occup Environ Med. 2020;62:e94–101. http//doi.org/10.1097/JOM.0000000000001805Christensen MC, Wong CMJ, Baune BT. Symptoms of major depressive disorder and their impact on psychosocial functioning in the different phases of the disease: do the perspectives of patients and healthcare providers differ? Front Psychiatry. 2020;11:280. http//doi.org/10.3389/fpsyt.2020.00280Christensen MC, Wong CMJ, Baune BT. Symptoms of major depressive disorder and their impact on psychosocial functioning in the different phases of the disease: do the perspectives of patients and healthcare providers differ? Front Psychiatry. 2020;11:280. http//doi.org/10.3389/fpsyt.2020.00280Christensen MC, Schmidt S, Grande I. The RECONNECT study: Effectiveness of vortioxetine (10–20 mg/day) in patients with major depressive disorder comorbid with generalized anxiety disorder. Poster presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, Lisbon, Portugal, 2–5 October 2021.Christensen MC, Schmidt S, Grande I. The RECONNECT study: Effectiveness of vortioxetine (10–20 mg/day) in patients with major depressive disorder comorbid with generalized anxiety disorder. Poster presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, Lisbon, Portugal, 2–5 October 2021.Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021; 283:472–9. http//doi.org/10.1016/j.jad.2020.11.106Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021; 283:472–9. http//doi.org/10.1016/j.jad.2020.11.106Galanopoulos A, Tsiolka E, Ntounas P et al. Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with MDD in Greece treated with vortioxetine: a patient-rated evaluation. Eur Psychiatry. 2021;64(1):334. http//doi.org/10.1192/j.eurpsy.2021.895Galanopoulos A, Tsiolka E, Ntounas P et al. Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with MDD in Greece treated with vortioxetine: a patient-rated evaluation. Eur Psychiatry. 2021;64(1):334. http//doi.org/10.1192/j.eurpsy.2021.895Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14:81–89. http//doi.org/10.1080/17460441.2019.1546691Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14:81–89. http//doi.org/10.1080/17460441.2019.1546691Iovieno N, Papakostas GI, Feeney A et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021; 82:20r13682. http//doi.org/10.4088/JCP.20r13682Iovieno N, Papakostas GI, Feeney A et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021; 82:20r13682. http//doi.org/10.4088/JCP.20r13682IsHak WW, James DM, Mirocha J et al. Patientreported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016; 7:160–169. http//doi.org/10.1177/2040622316639769IsHak WW, James DM, Mirocha J et al. Patientreported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016; 7:160–169. http//doi.org/10.1177/2040622316639769Kan K, Jörg F, Buskens E et al. Patients’ and clinicians’perspectives on relevant treatment outcomes in depression: qualitative study. BJPsych Open. 2020;6:e44. http//doi.org/10.1192/bjo.2020.27Kan K, Jörg F, Buskens E et al. Patients’ and clinicians’perspectives on relevant treatment outcomes in depression: qualitative study. BJPsych Open. 2020;6:e44. http//doi.org/10.1192/bjo.2020.27Lam RW, Parikh SV,Michalak EE et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27:142–149.Lam RW, Parikh SV,Michalak EE et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27:142–149.Oluboka OJ, Katzman MA, Habert J et al. Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 2018;21:128–144. http//doi.org/10.1093/ijnp/pyx081Oluboka OJ, Katzman MA, Habert J et al. Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 2018;21:128–144. http//doi.org/10.1093/ijnp/pyx081Salcedo B. The Comorbidity Of Anxiety And Depression.National Alliance on Mental Illness. 2018;19:325-333.Salcedo B. The Comorbidity Of Anxiety And Depression.National Alliance on Mental Illness. 2018;19:325-333.Saveanu R, Etkin A, Duchemin AM et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015; 61:1–12. http//doi.org/10.1016/j.jpsychires.2014.12.018Saveanu R, Etkin A, Duchemin AM et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015; 61:1–12. http//doi.org/10.1016/j.jpsychires.2014.12.018Sheehan DV, Nakagome K, Asami Y et al. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313. http//doi.org/10.1016/j.jad.2017.02.029Sheehan DV, Nakagome K, Asami Y et al. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313. http//doi.org/10.1016/j.jad.2017.02.029Wang G, Tan KHX, Ren H, Hammer-Helmich L. Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT Study.Neuropsychiatr Dis Treat. 2020;6:749–759. http//doi.org/10.2147/NDT.S230403Wang G, Tan KHX, Ren H, Hammer-Helmich L. Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT Study.Neuropsychiatr Dis Treat. 2020;6:749–759. http//doi.org/10.2147/NDT.S230403Yang YK, Chen CS, Tsai CFet al. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin. 2021;37:2163–2173. http//doi.org/10.1080/03007995.2021.1980869Yang YK, Chen CS, Tsai CFet al. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin. 2021;37:2163–2173. http//doi.org/10.1080/03007995.2021.1980869

The authors declare that there are no conflicts of interest present.